Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBIO
CUSIPN/A
Phone617-945-7361
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees61
Outstanding Shares45,140,000
Market Cap$481.21 million
Translate Bio (NASDAQ:TBIO) Frequently Asked Questions
What is Translate Bio's stock symbol?
Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."
How were Translate Bio's earnings last quarter?
Translate Bio Inc (NASDAQ:TBIO) announced its quarterly earnings results on Thursday, August, 9th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $3.64. View Translate Bio's Earnings History.
When is Translate Bio's next earnings date?
What price target have analysts set for TBIO?
3 analysts have issued twelve-month price objectives for Translate Bio's shares. Their forecasts range from $20.00 to $25.00. On average, they expect Translate Bio's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 114.9% from the stock's current price. View Analyst Price Targets for Translate Bio.
What is the consensus analysts' recommendation for Translate Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Translate Bio.
Who are some of Translate Bio's key competitors?
Some companies that are related to Translate Bio include Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Rubius Therapeutics (RUBY), Solid Biosciences (SLDB), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Audentes Therapeutics (BOLD), DBV TECHNOLOGIE/S (DBVT), Iovance Biotherapeutics (IOVA), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Avrobio (AVRO) and BAVARIAN NORDIC/S (BVNRY).
Who are Translate Bio's key executives?
Translate Bio's management team includes the folowing people:
- Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 49)
- Dr. Michael W. Heartlein, Chief Scientific Officer & CTO (Age 59)
- Mr. John R. Schroer CFA, CFO & Treasurer (Age 53)
- Mr. Paul D. Burgess J.D., Gen. Counsel (Age 45)
- Ms. Paula A. Cloghessy, Sr. VP of Human Resource (Age 47)
When did Translate Bio IPO?
(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO.
When did the company's quiet period expire?
Translate Bio's quiet period expired on Tuesday, August 7th. Translate Bio had issued 9,350,000 shares in its public offering on June 28th. The total size of the offering was $121,550,000 based on an initial share price of $13.00. During the company's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Has Translate Bio been receiving favorable news coverage?
News articles about TBIO stock have trended somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Translate Bio earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave news articles about the company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Translate Bio.
Who are Translate Bio's major shareholders?
Translate Bio's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (13.99%), Omega Fund Management LLC (5.44%), Bain Capital Public Equity Management LLC (2.16%), Federated Investors Inc. PA (1.59%), Luminus Management LLC (0.34%) and BlackRock Inc. (0.34%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Institutional Ownership Trends for Translate Bio.
Which major investors are buying Translate Bio stock?
TBIO stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Omega Fund Management LLC, Bain Capital Public Equity Management LLC, Federated Investors Inc. PA, Luminus Management LLC, BlackRock Inc., Millennium Management LLC and Laurion Capital Management LP. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View Insider Buying and Selling for Translate Bio.
How do I buy shares of Translate Bio?
Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Translate Bio's stock price today?
One share of TBIO stock can currently be purchased for approximately $10.7050.
How big of a company is Translate Bio?
Translate Bio has a market capitalization of $481.21 million. Translate Bio employs 61 workers across the globe.
How can I contact Translate Bio?
Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.
MarketBeat Community Rating for Translate Bio (NASDAQ TBIO)
MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote "Outperform" if you believe TBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
